Investment Summary |
|
|---|---|
| Date | 2022-10-04 |
| Target | Laboratoire X.O |
| Sector | Life Science |
| Investor(s) | Stanley Capital |
| Sellers(s) | Novalpina Capital |
| Deal Type | Secondary Buyout |
SEARCH BY
Stanley Capital is a private equity partnership that pursues healthcare and technology investments. The Firm targets businesses valued from $250 million to $2.5 billion with defensible business models and opportunities for growth. Stanley Capital was formed in 2019 and is headquartered in London.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Secondary Buyout M&A Deals | 1 of 2 |
| Country: France M&A | 1 of 1 |
| Year: 2022 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-01 |
Qinecsa Solutions
London, United Kingdom Qinecsa Solutions is a global provider of pharmacovigilance software and services. Qinecsa Solutions is based in London, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-11 |
Noden Pharma DAC
Dublin, Ireland Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market, and sell Tekturna® and Tekturna HCT (or Rasilez and Rasilez HTC outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg, and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland. |
Sell | - |
Novalpina Capital is an independent European private equity firm that invests in middle-market companies. Novalpina Capital was established in 2017 and is headquartered in London.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Secondary Buyout M&A Deals | 1 of 1 |
| Country: France M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-11 |
Laboratoire X.O
Saint-Cloud, France Laboratoire X.O is a pharmaceutical company offering drugs, medical devices, and cosmetic products. Laboratoire X.O was founded in 2015 and is based in Saint-Cloud, France. |
Buy | - |
